Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
3.715
-0.145 (-3.76%)
Jun 17, 2025, 4:00 PM - Market closed
Cardiff Oncology Employees
As of December 31, 2024, Cardiff Oncology had 33 total employees, including 32 full-time and 1 part-time employees. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
$17,788
Profits / Employee
-$1,481,152
Market Cap
247.14M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CRDF News
- 15 days ago - Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology: Buying The First-Line Onvansertib Strategy - Seeking Alpha
- 5 weeks ago - Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon - Seeking Alpha
- 7 weeks ago - Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewsWire
- 2 months ago - Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 3 months ago - Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript - Seeking Alpha